Total Payments
$270,419
2024 Payments
$10,733
Companies
23
Transactions
151
Payment Breakdown by Category
Consulting$202,406 (74.8%)
Research$38,739 (14.3%)
Travel$22,205 (8.2%)
Other$4,500 (1.7%)
Food & Beverage$2,569 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $202,406 | 60 | 74.8% |
| Unspecified | $38,739 | 19 | 14.3% |
| Travel and Lodging | $22,205 | 42 | 8.2% |
| Honoraria | $4,500 | 1 | 1.7% |
| Food and Beverage | $2,569 | 29 | 0.9% |
Payments by Type
General
$231,680
132 transactions
Research
$38,739
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $56,193 | 22 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $36,060 | 9 | $0 (2018) |
| Novo Nordisk Inc | $28,949 | 20 | $0 (2024) |
| Merck Sharp & Dohme LLC | $27,654 | 25 | $0 (2023) |
| Takeda Development Center Americas, Inc. | $24,210 | 6 | $0 (2017) |
| Genentech, Inc. | $19,510 | 9 | $0 (2021) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $15,334 | 7 | $0 (2018) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $10,845 | 9 | $0 (2022) |
| Avid Radiopharmaceuticals, Inc. | $9,782 | 4 | $0 (2020) |
| EISAI INC. | $7,428 | 9 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,733 | 8 | Novo Nordisk Inc ($10,318) |
| 2023 | $11,552 | 12 | Novo Nordisk Inc ($6,639) |
| 2022 | $34,488 | 25 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($8,885) |
| 2021 | $19,888 | 13 | GW Research Limited ($6,151) |
| 2020 | $38,027 | 14 | Eli Lilly and Company ($19,530) |
| 2019 | $35,327 | 20 | Eli Lilly and Company ($19,451) |
| 2018 | $37,190 | 15 | Takeda Pharmaceuticals U.S.A., Inc. ($12,510) |
| 2017 | $83,215 | 44 | Takeda Development Center Americas, Inc. ($24,210) |
All Payment Transactions
151 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/15/2024 | Abbott Laboratories | INFINITY (Device) | Travel and Lodging | In-kind items and services | $405.96 | General |
| Category: Neuromodulation | ||||||
| 08/15/2024 | Abbott Laboratories | INFINITY (Device) | Travel and Lodging | In-kind items and services | $9.02 | General |
| Category: Neuromodulation | ||||||
| 06/05/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $7,406.25 | General |
| 06/05/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $673.09 | General |
| 06/05/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $527.89 | General |
| 06/05/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $522.02 | General |
| 06/05/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $438.73 | General |
| 06/04/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 10/30/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $22.29 | General |
| 10/12/2023 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $5,906.25 | General |
| 10/12/2023 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $430.94 | General |
| 10/12/2023 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $205.46 | General |
| 10/12/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $81.18 | General |
| 10/12/2023 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $14.74 | General |
| 09/22/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,368.00 | General |
| 09/06/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,220.00 | General |
| Category: NEUROSCIENCE | ||||||
| 07/17/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $30.77 | General |
| 07/17/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.41 | General |
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $415.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 01/04/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,830.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/15/2022 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| 10/21/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $460.19 | General |
| Category: PSYCHIATRY | ||||||
| 10/21/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $350.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/21/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $79.19 | General |
| Category: PSYCHIATRY | ||||||
| 10/21/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $43.20 | General |
| Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | Genentech, Inc. | $19,510 | 9 |
| Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD | Takeda Development Center Americas, Inc. | $12,510 | 3 |
| Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD | Takeda Pharmaceuticals U.S.A., Inc. | $3,300 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,575 | 2 |
| ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | Eli Lilly and Company | $990.00 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $438.81 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $415.00 | 1 |
About Dr. Lon Schneider, MD
Dr. Lon Schneider, MD is a Psychiatry healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922022201.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lon Schneider, MD has received a total of $270,419 in payments from pharmaceutical and medical device companies, with $10,733 received in 2024. These payments were reported across 151 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($202,406).
Ad
Practice Information
- Specialty Psychiatry
- Location Los Angeles, CA
- Active Since 07/27/2006
- Last Updated 11/27/2023
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1922022201
Products in Payments
- Non-Covered Product (Drug) $19,010
- MK-8931 (Drug) $18,993
- Actos (Drug) $15,810
- REXULTI (Drug) $15,118
- MK-8189 (Drug) $4,275
- Dronabinol (OS) (Drug) $3,062
- ADLARITY (Drug) $2,240
- INFINITY (Device) $414.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Los Angeles
Dr. Walter Ling, Md, MD
Psychiatry — Payments: $397,562
Psychiatry $397,562
Dr. Jakub Juros, Md, MD
Psychiatry — Payments: $363,152
Psychiatry $363,152
John Brooks, M.d, M.D
Psychiatry — Payments: $134,275
Psychiatry $134,275
Stephen Marder, Md, MD
Psychiatry — Payments: $119,068
Psychiatry $119,068
Alexander Bystritsky
Psychiatry — Payments: $55,320
Psychiatry $55,320
Timothy Fong, Md, MD
Psychiatry — Payments: $54,008
Psychiatry $54,008